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Abstract: Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first enzyme 
of the hexosamine biosynthetic pathway. It transfers an amino group from glutamine to 
fructose-6-phosphate to yield glucosamine-6-phosphate, thus providing the precursor for 
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) synthesis. UDP-GlcNAc is an 
essential substrate for all mammalian glycosylation biosynthetic pathways and N-glycan 
branching is especially sensitive to alterations in the concentration of this sugar nucleotide. 
It has been reported that GFPT1 mutations lead to a distinct sub-class of congenital 
myasthenic syndromes (CMS) termed “limb-girdle CMS with tubular aggregates”. CMS are 
hereditary neuromuscular transmission disorders in which neuromuscular junctions are 
impaired. To investigate whether alterations in protein glycosylation at the neuromuscular 
junction might be involved in this impairment, we have employed mass spectrometric 
strategies to study the N-glycomes of myoblasts and myotubes derived from two healthy 
controls, three GFPT1 patients, and four patients with other muscular diseases, namely CMS 
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caused by mutations in DOK7, myopathy caused by mutations in MTND5, limb girdle 
muscular dystrophy type 2A (LGMD2A), and Pompe disease. A comparison of the relative 
abundances of bi-, tri-, and tetra-antennary N-glycans in each of the cell preparations revealed 
that all samples exhibited broadly similar levels of branching. Moreover, although some 
differences were observed in the relative abundances of some of the N-glycan constituents, 
these variations were modest and were not confined to the GFPT1 samples. Therefore, 
GFPT1 mutations in CMS patients do not appear to compromise global N-glycosylation 
in muscle cells. 
Keywords: congenital myasthenic syndromes; glutamine-fructose-6-phosphate transaminase 1; 
glycosylation; mass spectrometry 
 
1. Introduction 
Protein glycosylation, the attachment of carbohydrate chains to proteins, is a common post-translational 
modification occurring ubiquitously in eukaryotic cells. Intriguingly, mutations in genes encoding 
protein glycosylation enzymes, or enzymes synthesising the building blocks for protein glycosylation, 
have recently been identified to cause neuromuscular transmission defects called congenital 
myasthenic syndromes (CMS). The first of these genes to be correlated with CMS was GFPT1 
(glutamine-fructose-6-phosphate transaminase 1). Mutations in GFPT1 cause a distinct sub-class of 
CMS referred to as “limb-girdle CMS with tubular aggregates” [1,2]. Subsequently, mutations in three 
genes encoding enzymes of the protein N-glycosylation pathway (DPAGT1, ALG2 and ALG14) were 
also found to cause limb-girdle CMS [3,4]. The GFPT1 gene encodes a homodimeric, cytoplasmic 
enzyme that catalyses the first step of the hexosamine biosynthetic pathway [1]. Thus GFPT1 converts 
fructose-6-phosphate and glutamine into glucosamine-6-phosphate and glutamate; the end product of 
this pathway is uridine diphospho-N-acetylglucosamine (UDP-GlcNAc), which is a basic substrate not 
only for protein N- and O-linked glycosylation, but also for lipid glycosylation, proteoglycan synthesis, 
and O-GlcNAc glycosylation [1]. Currently it is not clear which of these pathways is affected most by 
lower levels of UDP-GlcNAc caused by GFPT1 deficiency. However, clinical presentation of CMS 
patients with mutations in DPAGT1, ALG2 and ALG14 is very similar to GFPT1 CMS, suggesting that 
impaired protein N-glycosylation might be the molecular defect underlying GFPT1 CMS. N-glycosylation 
is crucial for the assembly and function of a number of key molecules at the neuromuscular junction, 
like the acetylcholine receptor, the muscle-specific kinase (MuSK), and agrin. However, it is currently 
not clear why muscles, or more specifically the neuromuscular junctions, are more vulnerable than other 
tissues to GFPT1 deficiency. 
We set out to determine whether protein N-glycosylation is impaired or modified in the muscles  
of CMS patients with GFPT1 mutations. Specifically we employed mass spectrometric glycomic 
methodologies to rigorously characterise N-glycosylation in primary myoblasts from patients with 
GFPT1 mutations, as well as myotubes obtained by their in vitro differentiation. As controls for these 
analyses, we analysed myoblasts from two healthy controls and four patients with muscular diseases that 
have not previously been linked to glycosylation, namely CMS caused by mutations in DOK7, myopathy 
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caused by mutations in MTND5, limb girdle muscular dystrophy type 2A (LGMD2A) caused by 
mutations in the CAPN3 gene encoding calpain-3, and Pompe disease caused by mutations in the GAA 
gene encoding acid maltase responsible for breaking down glycogen in lysosomes. Unexpectedly, 
no impairment of N-glycosylation was observed in the GFPT1 patients’ myoblasts or myotubes. 
2. Results and Discussion 
2.1. Optimisation of Myoblast Culture Conditions 
Due to the fact that muscle biopsies do not provide sufficient sample for glycomic analysis we first 
established suitable cell culture conditions for producing the required cell counts (>106) whilst minimising 
the amount of foetal calf serum (FCS) present in the culture medium. The latter was important because 
it is known that FCS derived glycans frequently co-purify with cell-derived glycans during glycomic 
analyses [5]. We found that culturing in media containing 15% FCS was optimal for our glycomics 
experiments (see Figure S1). 
2.2. Glycomic Analysis of Patient and Control Myoblasts Reveals no Impairment in N-Glycosylation 
Myoblasts were cultured from three GFPT1 patients, one DOK7 patient, one MTND5 patient, one 
LGMD2A patient, one Pompe disease patient, and two healthy controls. MALDI-TOF N-glycomic 
profiling was performed on duplicate myoblast preparations with high quality data being acquired in all 
instances although minor glycans were not observed in GFPT1 patient 3 whose myoblasts were difficult 
to culture. Representative MALDI-TOF spectra from a healthy control, a GFPT1 patient and the DOK7 
patient are shown in Figure 1. MALDI data for the other patients and control are reproduced in 
Supplementary Information (see Figure S2). 
Figure 1 shows that myoblast N-glycans comprise both high mannose and complex (bi-, tri-, and 
tetraantennary) structures. Some common characteristics of mammalian cell N-glycomes [6,7] were observed, 
such as core fucosylated GlcNAc, LacNAc antenna building blocks which, in some cases, are tandemly 
repeated to produce oligo-LacNAc extensions, and NeuAc-capped antennae. Significantly, the N-glycan 
profile of healthy control 1 showed a broadly similar pattern to those of GFPT1 patient 1 and the 
DOK7 patient. 
To investigate whether the GFPT1 patients exhibited impaired N-glycan branching, we categorised 
the N-glycans into families with differing levels of sialylation and then compared glycan abundances 
within these families. We first checked that sialylation levels were similar in the different myoblast 
samples. We did this by calculating abundance ratios of pairs of glycans where one member of the pair 
had one more sialic acid than the other but otherwise the pair had identical compositions. The results of 
these calculations are shown in Figure 2 for the various myoblast samples. The data show that sialylation 
patterns are broadly similar for all samples. 
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(C) 
Figure 1. Annotated MALDI-TOF MS spectra of permethylated N-glycans of myoblasts from healthy control 1 (A), GFPT1 patient 1 (B), and 
the DOK7 patient (C). In each of A, B and C, the top panel shows the full spectrum of glycans and the bottom panel amplifies the mass range 
Biomolecules 2015, 5 2764 
 
where the majority of tri- and tetra-antennary glycans are found, the starting point and ending point of which have been indicated by red arrows. 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are [M + Na]+. The number indicated in the 
spectra is the mass to charge ratio (m/z) of the corresponding glycan ion. Since the ion is monocharged, the value of m/z is equal to the molecular 
weight value of the glycan. Annotations are based on the molecular weight, N-glycan biosynthetic pathway, and MS/MS data. Glycans at m/z 
2966, 3777, and 4587 are clearly annotated, which is due to the fact that their structures are unequivocal because each antenna is capped with a 
sialic acid and thus they are homogeneous bi-, tri-, and tetraantennary glycans. However, the glycan structure is not always as unequivocal as the 
glycan at m/z 2966 as biosynthetically non-fully sialylated glycan molecular ion species could be made up of mixtures of structural isoforms. 
Therefore, for those heterogeneous multiantennary structures with extended LacNAc repeats, the annotations are simplified throughout by using 
biantennary structures with the extensions and NeuAcs listed outside a bracket.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
 
Figure 2. Comparison of N-glycan sialylation in the myoblasts. Each point in the graph indicates a ratio which was obtained by comparing the relative 
intensity (RI) of one glycan to that of another glycan which possesses one fewer NeuAc. The numbers in the brackets correspond to the m/z of 
the comparing glycans. 
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For each family of sialylated glycans we then compared the abundance ratios of pairs of glycans 
differing in composition by a single LacNAc moiety. For example Figure 3 shows comparative data for 
mono-sialylated (panel A) and non-sialylated (panel B) glycans containing from two to six LacNAc 
units. All samples showed a similar profile of relative abundances, albeit there is a two to three-fold 
divergence of ratios when comparing four LacNAcs with three LacNAcs (for example m/z 3504 and 
3055, panel A), with the GFPT1 samples showing somewhat higher levels of the former than observed 
in the other samples. 
These unexpected results did not support our hypothesis that branching might be impaired in GFPT1 
myoblasts. Indeed they suggested that multiantennary glycans were possibly slightly more abundant in 
GFPT1 patients than in controls. However, it is important to note that increasing numbers of LacNAc 
units is not necessarily indicative of increased branching because these moieties can be present in extended 
oligo-LacNAc antennae rather than as additional antennae. Indeed the MALDI data in Figure 1 confirm that 
myoblasts are capable of extending their antennae because many of the glycans at high mass have more 
than the four LacNAc moieties that are the basis of a tetra-antennary glycan. Fortunately isomeric glycans 
differing in branching and oligo-LacNAc extensions can be readily distinguished and their abundances 
compared by analysing characteristic fragment ions in MS/MS experiments. For example Figure 4 shows 
MS/MS spectra obtained from the monosialylated glycan with three lacNAc units (m/z 3055) in the 
MALDI data (see Figure 1) for healthy control 1, GFPT1 patient 1 and the DOK7 patient. Two antennae 
arrangements are consistent with this composition: triantennary and/or biantennary with one LacNAc 
extension. As shown in the annotations on the spectra and the cartoons in Figure 4, the MS/MS spectra 
are dominated by fragment ions arising from loss of a single terminal LacNAc, with or without sialic 
acid. These fragment ions can be derived from both the bi-and tri-antennary options. Nevertheless, there 
are several fragment ions that are diagnostic for the extended biantennary structure. These are observed 
at m/z 935, 1781, and 2142. All are minor. Importantly, their abundances relative to the major fragment 
ions are similar in the three samples. We estimate from abundance comparisons that m/z 3055 is 
comprised of about 90% tri-antennary and 10% extended bi-antennary structures in all cases. 
MS/MS analyses of other glycans with similarly ambiguous compositions gave results comparable  
to those described above (see Figure S3). Taken together, the MS and MS/MS data provide convincing 
evidence that the patterns of branching and/or antennae extensions are very similar amongst the myoblasts 
from GFPT1 patients, healthy controls, and the other muscle disease patients studied. 
2.3. Sialic Acid Linkages Are Predominantly 2-3 in Myoblasts 
To obtain information on sialic acid linkages we carried out sialidase S digestion on a myoblast 
preparation from the DOK7 patient. This sialidase is specific for 2-3 linked sialic acid. As shown in 
Figure 5, digestion with sialidase S resulted in nearly complete desialylation of all of the core fucosylated 
N-glycans. A handful of minor sialylated glycans were observed at m/z 2431, 2880, and 3242. These  
2-6 linked sialylated bi- and tri-antennary glycans are lacking core fucose and are likely to be derived 
from FCS in the culture medium (see Section 2.1). We conclude that the sialic acid in the myoblast  
N-glycans is mainly 2-3 linked. 
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(A) 
 
(B) 
Figure 3. Comparison of the relative intensities of a family of mono-sialylated glycans with different numbers of LacNAc (A) in myoblasts; 
comparison of the relative intensities of a family of non-sialylated glycans with different numbers of LacNAc (B) in myoblasts. Each point in 
the graph indicates a ratio which was obtained by comparing the relative intensity (RI) of one glycan to that of the corresponding glycan which 
possesses one fewer LacNAc moiety. The number under the glycan structure is the m/z value of the glycan; this number is increasing with the 
addition of LacNAc moiety. In each comparison, the numbers in the brackets correspond to the m/z of the comparing glycans.  GlcNAc,  
 Man,  Gal,  Fuc,  NeuAc. 
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Figure 4. Cont. 
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Figure 4. MALDI-TOF/TOF MS/MS spectra of the permethylated N-glycan at m/z 3055 [M + Na]+ in myoblasts from healthy control 1 (A), 
GFPT1 patient 1 (B), and the DOK7 patient (C). Assignments of the fragment ions are indicated on the cartoons and on the spectra the horizontal 
red arrows show antennae losses whilst antennae-derived fragment ions are annotated with their sequences. The number indicated above  
the peak in the spectra is the m/z value of the fragment ion (resulting ion) that has been detected by the mass spectrometry.  GlcNAc,  Man, 
 Gal,  Fuc,  NeuAc. 
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Figure 5. Cont. 
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(B) 
Figure 5. Annotated MALDI-TOF MS spectra of permethylated N-glycans (A) and sialidase S treated N-glycans (B) of myoblasts from the DOK7 
patient. In each of A, B and C, the top panel shows the full spectrum of glycans and the bottom panel amplifies the mass range where the majority 
of tri- and tetra-antennary glycans are found, the starting point and ending point of which have been indicated by red arrows. Profiles were 
obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are [M + Na]+. The number indicated in the spectra is the 
mass to charge ratio (m/z) of the corresponding ion. Since the ion is monocharged, the value of m/z is equal to the molecular weight value of 
the glycan. Annotations are based on the molecular weight, N-glycan biosynthetic pathway and MS/MS data. Glycans at m/z 2966, 3777, and 
4587 are clearly annotated, which is due to the fact that their structures are unequivocal because each antenna is capped with a sialic acid and 
thus they are homogeneous bi-, tri-, and tetraantennary glycans. However, the glycan structure is not always as unequivocal as the glycan at m/z 
2966 as biosynthetically non-fully sialylated glycan molecular ion species could be made up of mixtures of structural isoforms. Therefore, for 
those heterogeneous multiantennary structures with extended LacNAc repeats, the annotations are simplified throughout by using biantennary 
structures with the extensions and NeuAcs listed outside a bracket.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
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2.4. Glycomic Analysis of Patient and Control Myotubes Reveals no Significant Difference  
in N-glycosylation 
Myotubes were obtained from all patients and controls by in vitro differentiation of their myoblasts 
in culture. They were then subjected to the same glycomic analyses as for myoblasts. Representative 
MALDI spectra are shown for healthy control 1, GFPT1 patient 1, and the DOK7 patient in Figure 6; 
spectra from other samples can be found in Supplementary Information (see Figure S4). Most samples 
gave good quality MALDI data, but, because sample quantities were more limited than for the myoblast 
preparations, low abundance glycans at high mass were not always observed. Nonetheless, we were able 
to draw firm conclusions from our data. Notably no significant differences were observed in the MALDI 
profiles from normal and GFPT1 samples (Figure 6A,B). Both showed a predominance of biantennary 
glycans, relatively high levels of tri- and tetraantennary glycans, and only very minor signals for glycans with 
more than four lacNAc units. The DOK7 myotubes similarly showed only minor signals for extended 
glycans but, in contrast to the normal and GFPT1 myotubes, their tri- and tetraantennary glycans were 
more abundant than biantennary structures. Similar glycomic profiling was performed on cells from 
healthy controls, GFPT1, MTND5, and LGMD2A patients. They all showed broadly similar glycan 
profiles as those observed in Figure 6A,B (see Figure S4). 
2.5. Discussion 
This is the first report of N-glycan profiles of in vitro cultured human myoblasts and human myotubes 
differentiating from myoblasts in vitro. The main findings of this work are that the N-glycan profiles of 
myoblasts (Figure 1) and myotubes (Figure 6) from GFPT1 patients and a selection of healthy and 
disease controls are broadly similar. All have comparable levels of high mannose and complex-type 
structures. The latter are core fucosylated and capped with 2-3 linked sialic acid. The relative abundances 
of the bi-, tri- and tetraantennary complex-type glycans are broadly similar in all samples except for the 
DOK7 myotubes whose multiantennary glycans were found to be somewhat more abundant than the 
other samples (Figure 6). 
These findings are unexpected as our initial hypothesis was that cells from GFPT1 patients would 
have changes in their N-glycan structures and particularly a reduction in N-glycan branching. This was 
based on data we recently published in which we characterised N-glycosylation of leukocytes from 
patients with mutations in phosphoglucomutase 3 (PGM3), another key enzyme in the biosynthesis of 
UDP-GlcNAc. A reduction in levels of tri-antennary and tetra-antennary N-glycans was observed which 
was rationalized by the fact that if a comparison is made of the GlcNAc transferases that are responsible 
for N-glycan branching the higher Km values (which in Michaelis-Menten kinetics corresponds to low 
substrate affinity and thus a low catalytic activity), are associated with GlcNAc transferase IV and 
GlcNAc transferase V that initiate the third and fourth antennae. Therefore by requiring higher substrate 
concentrations they will be most impaired by a reduction in UDP-GlcNAc concentration [8]. 
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Figure 6. Annotated MALDI-TOF MS spectra of permethylated N-glycans of myotubes from healthy control 1 (A); GFPT1 patient 1 (B) and 
the DOK7 patient (C). In each of A, B and C, the top panel shows the full spectrum of glycans and the bottom panel amplifies the mass range 
where the majority of tri- and tetra-antennary glycans are found, the starting point and ending point of which have been indicated by red arrows. 
Profiles were obtained from the 50% acetonitrile fraction from a C18 Sep-Pak column. All ions are [M + Na]+. The number indicated in the 
spectra is the mass to charge ratio (m/z) of the corresponding ion. Since the ion is monocharged, the value of m/z is equal to the molecular 
weight value of the glycan. Annotations are based on the molecular weight, N-glycan biosynthetic pathway and MS/MS data. Glycans at m/z 2966, 
3777 and 4587 are clearly annotated, which is due to the fact that their structures are unequivocal because each antenna is capped with a sialic 
acid and thus they are homogeneous bi-, tri- and tetraantennary glycans. However, the glycan structure is not always as unequivocal as the glycan 
at m/z 2966 as biosynthetically non-fully sialylated glycan molecular ion species could be made up of mixtures of structural isoforms. Therefore, 
for those heterogeneous multiantennary structures with extended LacNAc repeats, the annotations are simplified throughout by using biantennary 
structures with the extensions and NeuAcs listed outside a bracket.  GlcNAc,  Man,  Gal,  Fuc,  NeuAc. 
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Our findings that glycomic profiling of cells from GFPT1 patients is not altered does not however 
rule out that changes in N-glycosylation still plays role in the associated disease pathologies. It could be 
that occupancy of N-glycosylation sites is altered in the patients. The glycomic methods employed in the 
current work do not address occupancy. Indeed, assigning N-glycan occupancy is not possible in glycomic 
experiments on limited quantities of cells. It is also possible that changes in N-glycosylation are restricted 
to a subset of glycoproteins and that such subtle differences are lost in the general glycomic profiling. It 
could also be that the glycosylation in the muscle of the patient is different from that in the cultured cells 
or the glycosylation might have changed during the use and regeneration of muscle tissue (GFPT1 CMS 
is later onset than other CMS forms). In addition, the amount of glucose in the medium could influence 
the glucose flux and subsequently affect the amount of the primary substrate fructose-6-P [9]. 
The next challenge will be to perform detailed glycoproteomic analysis of specific glycoproteins such 
as acetylcholine receptor, the muscle-specific kinase (MuSK) and agrin. Indeed similarity between CMS 
due to GFPT1 mutations and CMS due to DPAGT1 mutations would suggest that reduced endplate 
acetylcholine receptor due to defective N-linked glycosylation is a primary disease mechanism in this 
disorder [3,10,11]. 
We chose the disease controls, namely CMS caused by mutations in DOK7, myopathy caused by 
mutations in MTND5, LGMD2A, and Pompe, as exemplars of muscle diseases which had not previously 
been found to exhibit defects in N-glycosylation. Very recently, however, a study has found that Pompe 
disease can lead to a Golgi-based glycosylation deficit in human skin fibroblast-derived induced pluripotent 
stem cells which were differentiated in culture to cardiomyocytes (iPSCCMs) [12]. Using a similar 
glycomics strategy to ours, Raval et al. have shown that there is a reduced diversity of multi-antennary 
structures and hyposialylation in Pompe iPSCCMs. It should be noted that even their control cells did 
not show the same high molecular weight multi-antennary N-glycans that we observed in this study. It 
is intriguing that our muscle cells are not showing comparable glycosylation defects. In future work it 
will be important to investigate whether glycosylation defects in Pompe are cell-specific. 
In conclusion we have performed the first detailed N-glycan glycomic analysis of myoblasts from 
healthy control, GFPT1 patients, a DOK7 patient, a MTND5 patient, a LGMD2A patient, and a Pompe 
disease patient. We also performed detailed structural analysis of N-glycans from myotubes derived  
from a healthy control, a GFPT1 patient, and a DOK7 patient. Whilst greatly expanding our knowledge 
of glycosylations in these cells we did not observe significant changes in disease and control  
N-glycan structures. 
3. Materials and Methods 
3.1. Patients 
Patients with limb-girdle CMS with tubular aggregates have been reported in two papers [1,2]. 
Detailed clinical data of the patients was previously published [2]. In brief, the patients presented with 
fatigable weakness restricted mostly to shoulder and pelvic girdle and minimal or no weakness of facial 
and ocular muscles. Response to treatment with acetylcholinesterase inhibitors was generally positive. 
The DOK7 patient has DOK7 mutations at c.1124_1127dupTGCC and a deletion of the last 11 bp of 
exon 4 on cDNA level (second mutation on genomic DNA level not identified), the MTND5 patient has 
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a MTND5 mutation at m.13051G>A, the Pompe disease patient has GAA mutations at c.-32-13T>G and 
c.52del (compound heterozygous), the limb girdle muscular dystrophy type 2A patient has CAPN3 
mutations at c.1322delG and c.1465C>T (compound heterozygous). Patients and controls were selected 
at the Newcastle University John Walton Muscular Dystrophy Research Centre, Institute of Genetic 
Medicine, Newcastle upon Tyne. Their diagnosis was obtained through a combination of clinical and 
morphological (muscle biopsy) methods and confirmed by genetic testing of the relevant genes. Collection 
of samples from patients and their use in research have been ethically approved by the NRES Committee 
North East—Newcastle and North Tyneside 1. All GFPT1 mutations resulted in a reduction of GFPT1 
protein amounts in patient muscle. No changes in protein localisation or enzyme activity were observed. 
3.2. Cell Culture 
Primary human skeletal myoblasts of the following patients were analysed: LGM9.3, (GFPT1 
mutations p.V199F and c.*22>A), and LGM5.3 and 5.5 (GFPT1 mutations p.M492T and c.*22C>A); 
patient numbers correspond to numbering in a previous paper [1]. LGM9.3, LGM5.3, and LGM5.5 are 
GFPT1 patient 1, 2, and 3 respectively. Six control myoblast lines were used, two from healthy 
individuals and four from diseases unrelated to GFPT1 (mutations in MTND5, DOK7, CAPN3, and 
GAA). Myoblasts from patients and controls were obtained from the MRC Centre for Neuromuscular 
Diseases Biobank Newcastle, UK, and the Muscle Tissue Culture Collection, Friedrich-Baur-Institute, 
Munich, Germany. The cells were isolated as previously described [13] and firstly grown in skeletal 
muscle growth medium (PromoCell, Heidelberg, Germany) supplemented with 5%, 10%, and 15% 
foetal calf serum. The final concentration of foetal calf serum in the growth medium was 15%. The 
concentration of glucose in the myoblast growth medium was 1 g/L. Myoblasts were differentiated to 
myotubes by switching to differentiation medium (DMEM with 2% horse serum) at a cell density of 
around 80%. The concentration of glucose in the differentiation medium was 4.5 g/L. Cells were grown 
in differentiation medium for one week. 
All studies were carried out with informed consent of the patients or their parents and were approved 
by institutional ethics review boards. 
3.3. Processing of Myoblasts and Myotubes to Acquire N- and O-glycans 
All myoblast and myotube samples were treated following a standard protocol [14]. Briefly, cells 
were suspended in lysis buffer (25 mM TRIS, 150 mM NaCl, 5 mM EDTA and 1% CHAPS (v/v), pH 7.4) 
before homogenisation and sonication were performed. The homogenates were subsequently dialysed 
against a 50 mM ammonia bicarbonate buffer, pH 7.5, after which the samples were lyophilized. 
Extracted glycoproteins were reduced and carboxymethylated and digested with trypsin. The digested 
glycopeptides were purified using a C18 cartridge (Oasis HLB Plus Waters) prior to the release of protein 
linked N-glycans by PNGase F (Roche Applied Science, East Sussex, UK) digest and O-linked glycans 
by reductive elimination. Released N- and O-glycans were permethylated and then purified using a  
Sep-pack C18 cartridge (Waters, Milford, MA, USA) prior to MS analysis. Sialidase cleavage was 
carried out using sialidase S (Prozyme Glyko, Cambridge, UK) in 50 mM sodium acetate, pH 5.5. 
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3.4. Mass Spectrometric Glycomic Analysis 
MS data were obtained via a Voyager MALDI-TOF (Applied Biosystems, Foster City, CA, USA) 
mass spectrometer. Purified permethylated glycans were dissolved in 10 μL methanol and 1 μL of the 
sample was mixed with 1 μL of matrix, 20 mg/mL 2,5-dihydroxybenzoic acid (DHB) in in 70% (v/v) 
aqueous methanol and loaded on to a metal target plate. The instrument was run in the reflectron positive 
ion mode. The accelerating voltage was 20 kV. 
MS/MS data were acquired using a 4800 MALDI-TOF/TOF mass spectrometer (AB SCIEX). In the 
MS/MS experiment the dissolved sample was dried and then re-dissolved in 10 μL methanol, 1 μL of 
the sample was mixed with 1 μL of matrix, 10 mg/mL diaminobenzophenone (DABP) in 70% (v/v) 
aqueous acetonitrile and loaded on to a metal target plate. The instrument was run in the reflectron 
positive ion mode. The collision energy was set to 1 kV with argon as the collision gas. The 4700 
calibration standard (mass standards kit for the 4700 proteomics analyzer, Applied Biosystems) was used 
as the external calibrant for the MS and MS/MS modes. 
3.5. Analyses of MALDI Data 
The MS and MS/MS data were processed employing Data Explorer Software from Applied Biosystems. 
The processed spectra were annotated using a glycobioinformatics tool, GlycoWorkBench [15]. Based 
on known biosynthetic pathways and susceptibility to PNGase F digestion, all N-glycans are presumed 
to have a Man1–6(Man1–3)Man1–4GlcNAc1–4GlcNAc core structure [16,17]. The symbolic 
nomenclature used in the spectra annotation is the same as the one used by the Consortium for 
Functional Glycomics (CFG) (http://www.functionalglycomics.org/) and the Essentials for Glycobiology 
on-line textbook (http://www.ncbi.nlm.nih.gov/books/NBK1931/figure/ch1.f5/?report=objectonl). 
Reproducibility and comparability were assessed by ANOVA (see Figure S5). 
4. Conclusions 
The glycomic analysis of myoblasts reveals that the patterns of branching and/or antennae extensions 
are very similar amongst the myoblasts from GFPT1 patients, healthy controls, and the other muscle 
disease patients studied. 
In addition, analysis of myotubes reveals that there is no significant difference in the MALDI profiles 
from GFPT1 patients, healthy controls, and the other muscle disease patients studied. 
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